Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients
Summary
- STRATEGY-PI study found that switching virologically suppressed patients from a boosted PI plus emtricitabine/tenofovir DF to single-tablet, once-daily cobicistat/elvitegravir/emtricitabine/tenofovir DF was well-tolerated and noninferior to continuing boosted PI-based therapy at Week 48 (Capsule Summary)[Arribas 2014]
- Switch strategy FDA approved for virologically suppressed patients (HIV-1 RNA < 50 copies/mL) with stable disease for ≥ 6 months and no history of treatment failure [FDA COBI/EVG/FTC/TDF]
- Study 109 showed that switching from tenofovir DF–containing ART regimen to cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide was associated with significantly higher rate of maintained virologic suppression, including in subset of patients receiving boosted atazanavir plus emtricitabine/tenofovir DF at baseline, and significant improvements in bone health and proximal tubular function endpoints at Week 48 vs continuing tenofovir DF–containing ART[Mills 2016]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content